TRULICITY 1.5 MG - AN OVERVIEW

The trial realized both its Principal endpoints, with semaglutide 2.four mg demonstrating statistically important and superior improvements in liver fibrosis without worsening of steatohepatitis, as well as resolution of steatohepatitis without worsening of liver fibrosis in people with MASH when compared with placebo.oneNumerous patterns and Life